aph-1105

APH-1105 is a novel small molecule drug developed as an alpha secretase modulator (amyloid precursor protein secretase modulator) for the treatment of Alzheimer's disease and dementia. It is designed to modulate the activity of amyloid precursor protein (APP) secretases, thereby influencing the production or processing of beta amyloid A4 protein, which plays a key role in Alzheimer's pathology. The drug is formulated as a sterile, pyrogen-free lyophilized powder intended for intranasal administration. Its primary indication is mild to moderate cognitive impairment due to Alzheimer's disease. The developer and sponsor for clinical studies is Aphios.